StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform

Financing Will Enable Stride to Move Multiple Programs Towards the Clinic DURHAM, N.C., June 13, 2018 -- (Healthcare Sales & Marketing Network) -- StrideBio, Inc, a US-based company developing novel AAV vectors for in vivo gene therapies announced toda... Biopharmaceuticals, Venture Capital, Personnel StrideBio, gene therapy, gene editing
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news